1. Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. Issue 9 (September 2019) Authors: Michallet, Anne-Sophie; Dilhuydy, Marie-Sarah; Subtil, Fabien; Rouille, Valerie; Mahe, Beatrice; Laribi, Kamel; Villemagne, Bruno; Salles, Gilles; Tournilhac, Olivier; Delmer, Alain; Portois, Christelle; Pegourie, Brigitte; Leblond, Veronique; Tomowiak, Cecile; de Guibert, Sophie; Orsini, Frederi... Journal: Lancet Issue: Volume 6:Issue 9(2019) Page Start: e470 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗